BD continually strives to deliver quality products, improve our offerings to better serve our customers and help optimize multicolor flow experiments. To this extent, we have launched an initiative to improve the performance of BD Horizon Brilliant™ Violet 605 (BV605) Research Use Only (RUO) Antibody Reagents. The BD Horizon™ BV605 Reagents will start being manufactured through a new process that provides enhanced photostability along with equivalent or improved brightness. You can also expect to see more BV605 RUO specificities being launched as a result of this process change.
BD Horizon™ BV605 RUO Reagents, excluding BD OptiBuild™ Reagents, will start to be manufactured via the new process beginning in September 2023. This change is expected to take 18–24 months to implement across the entire portfolio. As catalog numbers will not be changing, a product notice will temporarily be included with the reagent packaging as an indicator that the change has occurred for a particular catalog number.
What you can expect from the lots manufactured using the new process:
- Enhanced photostability
- Equivalent or improved brightness relative to the legacy process
- No changes to the catalog number, specificity, clone or dye
- A product notice will temporarily be included with the reagent packaging as an indication the change has occurred
See the product list below detailing which BD Horizon™ BV605 RUO Reagents have undergone the change. The table references the final lot made using the legacy manufacturing process and first lot produced through the new process.
Performance Data
Comparison of original and revised BD Horizon™ BV605 Reagents demonstrating similar or better performance.
A. Flow cytometric comparison of CD45 staining on mouse splenocytes using revised process BD Horizon™ BV605 (blue histogram) or legacy process BD Horizon™ BV605 (orange histogram) Rat Anti-Mouse CD45 Reagents.
Splenic leucocytes from a Balb/c mouse were preincubated with purified rat anti-mouse CD16/CD32 antibody (Mouse BD Fc Block™ Reagent). The cells were then stained with BV605 rat anti-mouse CD45 antibodies at 0.25 µg/T. BD Via-Probe™ Cell Viability 7-AAD Solution was added to cells right before analysis. The fluorescence histograms showing CD45 expression were derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) splenic leucocytes.
B. Flow cytometric comparison of CD45 staining on mouse splenocytes using revised process BD Horizon™ BV605 (left) or legacy process BD Horizon™ BV605 (right) Rat Anti-Mouse CD45 Reagents.
Splenic leucocytes from a Balb/c mouse were preincubated with purified rat anti-mouse CD16/CD32 antibody (Mouse BD Fc Block™ Reagent). The cells were then stained with BV605 rat anti-mouse CD45 antibodies at 0.25 µg/T. BD Via-Probe™ Cell Viability 7-AAD Solution was added to cells right before analysis. The bivariate pseudocolor density plots showing the correlated expression of CD45 versus side light-scatter (SSC-A) signals were derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) splenic leucocytes.
A. Flow cytometric comparison of CD3e staining on mouse splenocytes using revised process BD Horizon™ BV605 (blue histogram) or legacy process BD Horizon™ BV605 (orange histogram) Hamster Anti-Mouse CD3e Reagents.
Splenic leucocytes from a Balb/c mouse were preincubated with purified rat anti-mouse CD16/CD32 antibody (Mouse BD Fc Block™ Reagent). The cells were then stained with BV605 hamster anti-mouse CD3e antibodies at 0.5 µg/T. BD Via-Probe™ Cell Viability 7-AAD Solution was added to cells right before analysis. The fluorescence histograms showing CD3e expression were derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) splenic leucocytes.
B. Two-color flow cytometric comparison of CD3e staining on mouse splenocytes using revised process BD Horizon™ BV605 (left) or legacy process BD Horizon™ BV605 (right) Hamster Anti-Mouse CD3e Reagents.
Splenic leucocytes from a Balb/c mouse were preincubated with purified rat anti-mouse CD16/CD32 antibody (Mouse BD Fc Block™ Reagent). The cells were then stained with FITC rat anti-mouse CD4 and FITC rat anti-mouse CD8a antibodies and BV605 hamster anti-mouse CD3e antibodies at 0.5 µg/T. BD Via-Probe™ Cell Viability 7-AAD Solution was added to cells right before analysis. The bivariate pseudocolor density plots show the correlated expression patterns of CD3e versus CD4 and CD8a for gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) splenic leucocytes.
A. Flow cytometric comparison of CD19 staining on human peripheral blood lymphocytes using revised process BD Horizon™ BV605 (blue histogram) or legacy process BD Horizon™ BV605 (orange histogram) Mouse Anti-Human CD19 Reagents.
Whole blood was stained with BV605 mouse anti-human CD19 antibodies at 0.25 µg/T. Erythrocytes were lysed with BD FACS™ Lysing Solution. The fluorescence histograms showing CD19 expression were derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes.
B. Flow cytometric comparison of CD19 staining using revised process BD Horizon™ BV605 (left) or legacy process BD Horizon™ BV605 (right) Mouse Anti-Human CD19 Antibodies.
Whole blood was stained with BV605 mouse anti-human CD19 antibodies at 0.25 µg/T. Erythrocytes were lysed with BD FACS™ Lysing Solution. The bivariate pseudocolor density plots showing the correlated expression of CD19 versus side light-scatter (SSC-A) signals were derived from gated events with the forward and side light-scatter characteristics of intact leucocyte populations.
Product Transition Chart
| BV605 RUO Reagent Cat. No. | Species | Description | Clone | Last Lot Legacy Process |
First Lot New Process |
| 563059 | Mouse | Ms CD279 (PD-1) BV605 J43 50ug | J43 | 3184010 | 3236998 |
| 562723 | Human | Hu CD11B BV605 ICRF44 25Tst | ICRF44 | 3146211 | |
| 562721 | Human | Hu CD11B BV605 ICRF44 100Tst | ICRF44 | 3146209 | |
| 562989 | Human | Hu CD69 BV605 FN50 100Tst | FN50 | 3130907 | |
| 562724 | Human | Hu CD196 CCR6 BV605 11A9 50Tst | 11A9 | 3177669 | |
| 563144 | Iso Ctrl | Rat IgG2a Kpa ItCl BV605 R35-95 50ug | R35-95 | 3033368 | |
| 564165 | Human | Hu IL-2 BV605 MQ1-17H12 100Tst | MQ1-17H12 | 3177373 | |
| 564098 | Non-Hu Primate | NHP CD45 BV605 D058-1283 50Tst | D058-1283 | 3048574 | |
| 563930 | Human | Hu CD11c BV605 B-ly6 25Tst | B-ly6 | 3151670 | |
| 563929 | Human | Hu CD11c BV605 B-ly6 100Tst | B-ly6 | 3191603 | |
| 562979 | Human | Hu CD15 BV605 W6D3 25Tst | W6D3 | 3107761 | |
| 563052 | Mouse | Ms CD80 BV605 16-10A1 50ug | 16-10A1 | 3130908 | |
| 567691 | Human | Hu CD39 BV605 A1/CD39 100Tst | A1/CD39 | 3104429 | |
| 565998 | Human | Hu CD4 BV605 SK3 25Tst |
SK3 | 3207591 | |
| 562980 | Human | Hu CD15 BV605 W6D3 100Tst | W6D3 | 3107749 | |
| 563313 | Human | Hu IgD BV605 IA6-2 50Tst | IA6-2 | 3214603 | |
| 562987 | Iso Ctrl | Rat IgG1 Lam ITCL BV605 A110-1 50ug | A110-1 | 2293021 | |
| 564032 | Human | Hu CD183 BV605 1C6/CXCR3 50Tst | 1C6/CXCR3 | 3027125 | |
| 564047 | Human | Hu CD45 BV605 HI30 100Tst | HI30 | 3214600 | |
| 564048 | Human | Hu CD45 BV605 HI30 25Tst | HI30 | 3214602 |
For Research Use Only. Not for use in diagnostic or therapeutic procedures.